{"name":"Inna Chen, MD","slug":"inna-chen-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"TGFβ-B-15 peptide","genericName":"TGFβ-B-15 peptide","slug":"tgf-b-15-peptide","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"TGFβ-B-15 peptide","genericName":"TGFβ-B-15 peptide","slug":"tgf-b-15-peptide","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNN3plMERWZ2s3dzJFYnRKUWpMUUtjNXhfcHlDQUlDTng1N1ZRd0s4M3hqMzNNYWZ2Q1pYZFdHazZMaW1uQ2Nadlk1YkRxOFd5NW5Td3JJVWhTcVg5d0p5dEZNSG1WdEVjeWczTFBwMEIzZjB6NjBWUERoMml3S0dQV3BtUl9kQVBIalAzb1I2MDFwaFgycUhsVkdoZTk2UjNUdzZYeTJXaU9VTklmdEZ2Q0dRd3kyN1pqOVU5SkpvTW9CWU9pT09OUWM3TmlvTGl3ZGVuUW9IWVZIRFE0MHRCdA?oc=5","date":"2025-05-21","type":"pipeline","source":"The ASCO Post","summary":"Addition of Tocilizumab to Nab-Paclitaxel and Gemcitabine in First-Line Treatment of Advanced Pancreatic Cancer - The ASCO Post","headline":"Addition of Tocilizumab to Nab-Paclitaxel and Gemcitabine in First-Line Treatment of Advanced Pancreatic Cancer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}